Pathogenetic approaches to the treatment of chronic liver diseases with the presence of intrahepatic cholestasis
The article includes discussion of the problem of intrahepatic cholestatasis (IC), which can be the syndrome of acute and chronic liver diseases and separate disease with morphologic and biochemistry changes caused by disorders of bile outflow. The article describes the approaches to treatment using drugs affecting different stages of pathogenesis: geptral – bioactive compound and analog of natural in cellular ademetionine and ursodeoxycholic acid drugs (UAD). Geptral is a hepatoprotector with antidepressive activity and choleretic and cholekinetic action, detoxication, regeneration, antioxidant, antifibrotic and neuroprotective effects. UAD cause the decreasing of the concentration of hydrophobic bile acids in enterohepatic circulation, preventing its toxic effect on hepatocyte membranes and epithelium of biliary duct, and also have immunomodulating and anti-inflammatory effect.

Keywords: ursodeoxycholic acid, Geptral, bile acids, intrahepatic cholestatasis